首页> 外文期刊>Online journal of biological sciences >Measurement of the Gene Expression and Polymorphisms of c-myc and p53 Genes in HBV Infected Patients
【24h】

Measurement of the Gene Expression and Polymorphisms of c-myc and p53 Genes in HBV Infected Patients

机译:HBV感染患者中C-MYC和P53基因基因表达和多态性的测量

获取原文
           

摘要

This study explained the c-myc and p53 gene expression and polymorphisms in chronic (40), cirrhosis (30) and Hepatocellular Carcinoma, (HCC) (30) patients related to Hepatitis B Virus (HBV) infection and healthy control (50) in Egypt. Where, c-myc (intron 8) and p53 (codon 72) gene expression and polymorphisms were determined using qRT-PCR and PCR-RFLP techniques. The results showed that c-myc gene expression (2 -ddct ) was significantly increased in chronic (1.38), cirrhosis (1.47) and HCC (5.59) compared to the control group (1.00), while p53 gene expression (2 -ddct ) was significantly decreased compared to the control group (0.82, 0.65, 0.33 and 1.00, respectively). In HCC group, c-myc genotype (CC) was predominant (90%) more than cirrhosis, chronic and control (73.33, 22.5 and 6%, respectively), GG genotype was predominant in control (70%) more than chronic, cirrhosis and HCC groups (67.5, 6.66 and 6.66%, respectively) and GC genotype was high in control (24%) more than cirrhosis, chronic and HCC groups (20, 10 and 3.33%, respectively). p53 PP (88%) genotype was predominant in control more than chronic, cirrhosis and HCC groups (30, 30 and 6.66%, respectively), AA genotype was predominant in HCC group (73.33%) more than chronic, cirrhosis and control (50, 10 and 4%, respectively) and genotype PA was predominant in cirrhosis (60%) more than chronic, HCC and control (20, 20 and 8%, respectively). These results suggest clearly that both c-myc and p53 gene expression and polymorphisms influence clinical outcome and progression of HBV infection and then considered an accurate genetic biomarker to determine and predict the progression of HBV infection.
机译:本研究解释了慢性(40),肝硬化(30)和肝细胞癌,(HCC)(30)与乙型肝炎病毒(HBV)感染和健康控制(50)相关的患者的C-MYC和P53基因表达和多态性埃及。使用QRT-PCR和PCR-RFLP技术测定C-Myc(内含子8)和P53(密码子72)基因表达和多态性。结果表明,与对照组(1.00)相比,慢性(1.38),肝硬化(1.47)和HCC(5.59)中C-MYC基因表达(2 -DDCT)显着增加,而P53基因表达(2 -DDCT)与对照组相比(分别为0.82,0.65,0.33和1.00)显着降低。在HCC组中,C-MYC基因型(CC)是主要的(90%)超过肝硬化,慢性和对照(73.33,22.5和6%),GG基因型在对照中占主导地位(70%)超过慢性,肝硬化和HCC组(分别为67.5,6.66和6.66%)和GC基因型对照(24%)比肝硬化,慢性和HCC组(分别为20,10和3.33%)。 P53 PP(88%)基因型在对照中占主导地位,比慢性,肝硬化和HCC组(分别为30,30和6.66%),AA基因型在HCC组(73.33%)超过慢性,肝硬化和对照(50 ,分别为10和4%)和基因型Pa在肝硬化(60%)中占主导地位,超过慢性,HCC和对照(20,20和8%)。这些结果表明,C-MYC和P53基因表达和多态性都会影响HBV感染的临床结果和进展,然后被认为是一种准确的遗传生物标志物,以确定和预测HBV感染的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号